Loading stock data…
Humana Inc. (HUM)
$403.09+1.55 (+0.39%)
Market ClosedLast close Sep 8
Humana Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Humana Inc. in the Healthcare sector is trading at $403.09 with a market capitalization of $46.2B. Wall Street consensus targets $418.61 (23 analysts), implying a +3.8% move over the next 12 months. The stock is currently near its 52-week high of $428.88, remaining 44.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $40.87B↑ | $39.65B↑ | $32.52B↓ | $32.65B↑ | $32.39B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $1.15B↓ | $1.79B↑ | -$865.00M↓ | $302.00M↓ | $898.00M |
| Net Income | $694.00M↓ | $1.19B↑ | -$796.00M↓ | $195.00M↓ | $545.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, inclu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$46.16B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
36.72
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.88%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.66%
Volume
Today's trading volume
752,311
Recent News
Insurers Have Already Told Wall Street Which Advantage Plans Die on December 31. Members Are the Last to Know, and the Letter Isn’t Due Until October 2.
Insurers spent the summer telling Wall Street exactly which Medicare Advantage plans are disappearing on December 31. Enrolled members get a letter in October, a closing enrollment window in December, and a rare legal protection most will never realize they have.
UnitedHealth Stock Rises 39% in 6 Months: Should Investors Still Buy?
UNH's 39% six-month rally reflects improving medical costs, stronger earnings estimates and a sharper focus on profitable businesses.
1 High-Flying Stock for Long-Term Investors and 2 Facing Headwinds
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
DaVita (DVA) Has Investors Asking A Fresh Question
DaVita (DVA) is back in focus after two meaningful developments. The company expanded its value based care partnership with Humana for chronic kidney disease patients and agreed to a US$15 million settlement related to a prior data breach. Investors have been reacting to this mix of partnership news and legal resolution with a share price that is still up 58.64% year to date, despite a 30 day share price return of down 20.32%. The 3 year total shareholder return of 90.54% points to momentum...
If Your Advantage Plan Ends December 31 and You Do Nothing, You Wake Up January 1 in Original Medicare With No Drug Coverage and No Medigap.
Humana's non-renewal letters are already in the mail, and the deadline to act is closer than most affected members realize. Missing it by even one day changes what coverage options remain available and how much they cost.